The higher co-occurrence rates in Class II and III patients are particularly noteworthy, as BRAF-RAS co-mutations are traditionally considered rare or mutually exclusive in other cancer types, such as colorectal cancer where they occur in <1% of cases38. The gene discussed is BRAF; the disease is colorectal cancer.